N-甲基-N-(4-哌啶-1-苄基)甲胺 | 852180-55-3

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 哌啶类
• 中文名称: N-甲基-N-(4-哌啶-1-苄基)甲胺
• 英文名称: N-methyl-N-(4-piperidin-1-ylbenzyl)amine
• 英文别名: N-methyl-1-(4-piperidin-1-ylphenyl)methanamine
• CAS: 852180-55-3
• 化学式: C₁₃H₂₀N₂
• mdl: MFCD07348564
• 分子量: 204.31
• InChiKey: ABHBNGLDUNAXSR-UHFFFAOYSA-N

物化性质

• 沸点：
  332.5±25.0 °C(Predicted)
• 密度：
  1.004±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.3
• 重原子数：
  15
• 可旋转键数：
  3
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.538
• 拓扑面积：
  15.3
• 氢给体数：
  1
• 氢受体数：
  2

安全信息

• 危险等级：
  IRRITANT
• 危险品标志：
  C
• 海关编码：
  2933399090

文献信息

• [EN] SMALL MOLECULE MODULATORS OF SIGMA-1 AND SIGMA-2 RECEPTORS AND USES THEREOF<br/>[FR] MODULATEURS À PETITES MOLÉCULES DE RÉCEPTEURS SIGMA-1 ET SIGMA-2 ET LEURS UTILISATIONS
  申请人：UNIV NORTHWESTERN

  公开号：WO2020112846A1

  公开（公告）日：2020-06-04

  This invention is in the field of medicinal chemistry. In particular, the invention relates to a new class of small-molecules having a tetrahydroindazole structure which function as modulators (e.g., activators or inhibitors) of sigma-1 and/or sigma-2 receptors, and their use as therapeutics for the treatment of cancer and other diseases (e.g., neurological conditions) characterized with sigma-1 and/or sigma-2 receptor activity.

  这项发明属于药物化学领域。具体来说，该发明涉及一类具有四氢吲哚结构的小分子，其作为sigma-1和/或sigma-2受体的调节剂（例如，激活剂或抑制剂），以及它们作为治疗癌症和其他疾病（例如，具有sigma-1和/或sigma-2受体活性的神经系统疾病）的药物的用途。
• HETERO RING DERIVATIVE
  申请人：Takahashi Fumie

  公开号：US20120165309A1

  公开（公告）日：2012-06-28

  [Object] A novel and excellent method for preventing or treating rejection in the transplantation of various organs, allergy diseases, autoimmune diseases, hematologic tumor, or the like, based on a PI3Kδ-selective inhibitory action and/or an IL-2 production inhibitory action, and/or a B cell proliferation inhibitory action (including an activation inhibitory action), is provided [Means for Solution] It was found that a 3-substituted triazine or 3-substituted pyrimidine derivative exhibits a PI3Kδ-selective inhibitory action, and/or an IL-2 production inhibitory action, and/or a B cell proliferation inhibitory action (including an activation inhibitory action), and can be an agent for preventing or treating rejection in the transplantation of various organs, allergy diseases (asthma, atopic dermatitis, etc.), autoimmune diseases (rheumatoid arthritis, psoriasis, ulcerative colitis, Crohn's disease, systemic lupus erythematosus, etc.), hematologic tumor (leukemia etc.), or the like, thereby completing the present invention.

  [目标]提供一种基于PI3Kδ选择性抑制作用和/或IL-2产生抑制作用和/或B细胞增殖抑制作用（包括激活抑制作用）的新颖优良方法，用于预防或治疗各种器官移植、过敏性疾病、自身免疫性疾病、血液肿瘤等的排斥反应。 [解决方案]发现3-取代-1,3,5-三嗪或3-取代嘧啶衍生物表现出PI3Kδ选择性抑制作用和/或IL-2产生抑制作用和/或B细胞增殖抑制作用（包括激活抑制作用），可以作为预防或治疗各种器官移植、过敏性疾病（哮喘、特应性皮炎等）、自身免疫性疾病（类风湿性关节炎、银屑病、溃疡性结肠炎、克罗恩病、系统性红斑狼疮等）、血液肿瘤（白血病等）等排斥反应的药物，从而完成了本发明。
• COMPOUNDS AND METHODS FOR INHIBITING PHOSPHATE TRANSPORT
  申请人：ARDELYX, INC.

  公开号：US20140023611A1

  公开（公告）日：2014-01-23

  Compounds having activity as phosphate transport inhibitors, more specifically, inhibitors of intestinal apical membrane Na/phosphate co-transport, are disclosed. Methods associated with preparation and use of such compounds, as well as pharmaceutical compositions comprising such compounds, are also disclosed.

  本发明涉及具有磷酸盐转运抑制活性的化合物，更具体地涉及肠道顶端膜Na/磷酸盐共转运的抑制剂。本发明还涉及与制备和使用此类化合物相关的方法，以及包含此类化合物的制药组合物。
• HEPATITIS B ANTIVIRAL AGENTS
  申请人：Novira Therapeutics Inc.

  公开号：EP3312160A1

  公开（公告）日：2018-04-25

  The present invention includes a method of inhibiting, suppressing or preventing HBV infection in an individual in need thereof, comprising administering to the individual a therapeutically effective amount of at least one compound of the invention.

  本发明包括一种在有需要的个体中抑制、抑制或预防 HBV 感染的方法，包括向该个体施用治疗有效量的至少一种本发明化合物。
• CAMPTOTHECIN DERIVATIVE, PREPARATION METHOD THEREFOR AND APPLICATION THEREOF
  申请人：Marine Biomedical Research Institute Of Qingdao Co., Ltd.

  公开号：EP3808751A1

  公开（公告）日：2021-04-21

  The present invention is directed to compounds according to Formula I as well as to stereisomer, tautomer or pharmaceutically acceptable salts of such compounds. The invention also is directed to pharmaceutically acceptable compositions containing such compounds and associated methods for preparing and effect dose in treatment as well as the application in preparing medicine for preventing and/or treating cancers. The invention provides the novel derivatives which introduce methylenedioxy in the position of 10,11 and different groups in the position of 7. The derivatives of novel structure, and the raw materials are easily to obtain. In addition, the compounds in this invention have good cytotoxic activity in vitro and anti-tumor activity in vivo. Therefore, this kind of compounds have broad application foreground. The structure of derivatives are as follows:

  本发明涉及根据式 I 的化合物以及此类化合物的立体异构体、同系物或药学上可接受的盐。本发明还涉及含有此类化合物的药学上可接受的组合物、相关的制备方法和治疗效果剂量，以及在制备预防和/或治疗癌症的药物中的应用。本发明提供了在 10、11 位置引入亚甲基二氧和在 7 位置引入不同基团的新型衍生物，该衍生物结构新颖，原料易得。此外，本发明中的化合物具有良好的体外细胞毒性活性和体内抗肿瘤活性。因此，此类化合物具有广阔的应用前景。衍生物的结构如下